|March 4, 2014||Posted by admin under 2013, aao, vitreo-retina|
In a pro/con session during AAO 2013 Retina meeting, Thomas M. Aaberg Jr, MD, and Steven T. Charles, MD, argued the merits of office-based vitrectomy.
Rationale for. Primary reasons for making the switch include cost, convenience, and control, Dr. Aaberg said. Proper patient and case selection is essential, he cautioned. With that as the starting point, “In every case we’ve performed, we’ve been able to achieve all of our surgical goals,” he added.
He noted that safety (more…) (233)
|February 22, 2014||2014, Abstract, Glaucoma, Surgery|
Ex-Press shunt, trabeculectomy yield similar outcomes This multicenter, prospective, randomized study compared outcomes with trabeculectomy (61 eyes) and the Ex-Press glaucoma filtration implant (59 eyes) placed under a partial-thickness scleral flap. At two years follow-up, outcomes were similar in terms of mean IOPs, medication use, and surgical success. Although the Ex-Press group returned to baseline… more
|February 20, 2014||2014, AIOS, Conferences, news|
Dr Quresh Maskati takes over as President of AIOS A big & hearty congratulations to our own Dr Quresh on his installation as President of the All India Ophthalmological Society (AIOS) during the 2014 Annual Conference of the society held in the city of Agra in India. The society is safe and in competent hands… more
Risk factors for acute postoperative intraocular pressure elevation after phacoemulsification in glaucoma patients
|February 4, 2014||2014, Abstract, cataract, Glaucoma|
Risk factors for acute postoperative intraocular pressure elevation after phacoemulsification in glaucoma patients Author(s): Slabaugh M, Bojikian K, Moore D, Chen P Treatments discussed: acetazolamide PURPOSE To evaluate the risk factors for and frequency of an acute intraocular pressure (IOP) elevation (spike) after phacoemulsification in patients with glaucoma. (301)
|January 5, 2014||2014, news, Pharmacology, vitreo-retina|
FDA accepts Regeneron’s Eylea sBLA for standard review The supplemental Biologics License Application (sBLA) on Eylea intravitreal injection (aflibercept, Regeneron, Tarrytown, N.Y.) for the treatment of diabetic macular edema (DME) has been accepted by the Food and Drug Administration, with a targeted Prescription Drug User Fee Act date of August 18, 2014. The submission was… more
|December 18, 2013||Posted by admin under 2013, cataract, IOL, Surgery|
Healio_OSN: BLOG: Complications of glued IOL, by Priya Narang, MS. Read it here: http://ow.ly/rRsOX (281)
|December 12, 2013||Posted by admin under 2013, Conferences, POS|
POS-2013-CONFERENCE BROCHURE .(3.5MB PDF) (286)
|December 10, 2013||Posted by admin under Glaucoma, Pharmacology|
Author(s): Vandewalle E, Abegão Pinto L, Van Bergen T, Spielberg L, Fieuws S, Moons L, Spileers W, Zeyen T, Stalmans I
Treatments discussed: bevacizumab
AIMS To investigate the efficacy and safety of a single intracameral bevacizumab injection to improve the outcome of trabeculectomy.
METHODS A 12-month, prospective, randomised, double-masked, placebo-controlled trial. Patients with medically uncontrolled open-angle glaucoma scheduled for a primary trabeculectomy were recruited and randomised to receive 50 µL of either bevacizumab (1.25 mg) or placebo (balanced salt solution) peroperatively. Absolute success was defined as intraocular pressure (IOP) ≤18 mm Hg and>5 mm Hg with at least 30% reduction from baseline and no loss of light perception. (more…) (267)
|December 10, 2013||Posted by admin under Abstract, peadiatric, Pharmacology|
Author(s): Kiryazov K, Stefova M, Iotova V
Treatments discussed: brimonidine, brinzolamide, timolol
Topical ocular medications have been widely prescribed and successfully used in children for the management of different ophthalmic disorders. We present 2 infants admitted to our pediatric intensive care unit who developed altered state of consciousness, hypotonia, hypothermia, bradycardia, and apnea after instillation of ophthalmic drops. The second infant also had (more…) (565)
|December 9, 2013||Posted by admin under 2013, cataract, Glaucoma|
The CyPass Micro-Stent procedure for glaucoma can be safely combined with cataract surgery, according to 2-year results from the CYCLE trial. Investigators report that the procedure provided sustained control of intraocular pressure and reduced medication use.
“This procedure is an attempt to have surgeries for glaucoma that are safer and easier for the patient,” said investigator Brian Flowers, MD, from Fort Worth, Texas. “Current surgical treatments for glaucoma are associated with events such as suprachoroidal hemorrhage and bleb-related complications. Microinvasive surgical stenting of the supraciliary space may improve aqueous flow, with fewer complications,” he explained here at the American Academy of Ophthalmology (AAO) 2013 Annual Meeting.
There are 2 main approaches to minimally invasive glaucoma surgery, (more…) (303)